Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax
Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.
Benzinga ·